Find stories of hope, told by the people who motivate us every day to continue changing the standard in cancer care.
Each cell therapy we develop is uniquely designed for each patient, harnessing the power of the immune system to target and attack cancer. Our CAR T-cell therapy manufacturing process includes these 5 steps:
December 07, 2025
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025December 06, 2025
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple MyelomaDecember 06, 2025
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025November 03, 2025
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025